Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 4,340,000 shares, a drop of 18.1% from the June 30th total of 5,300,000 shares. Approximately 8.2% of the company’s stock are sold short. Based on an average daily volume of 817,600 shares, the days-to-cover ratio is currently 5.3 days.
Wall Street Analyst Weigh In
RGLS has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com assumed coverage on Regulus Therapeutics in a research report on Tuesday, April 16th. They set a “sell” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.75.
Check Out Our Latest Research Report on RGLS
Institutional Inflows and Outflows
Regulus Therapeutics Stock Performance
Shares of NASDAQ RGLS traded up $0.02 during midday trading on Friday, reaching $1.78. 1,509,376 shares of the company were exchanged, compared to its average volume of 835,089. The stock has a fifty day simple moving average of $2.02 and a 200 day simple moving average of $1.98. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79.
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.14). On average, equities research analysts expect that Regulus Therapeutics will post -0.59 earnings per share for the current year.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Featured Stories
- Five stocks we like better than Regulus Therapeutics
- What is the Hang Seng index?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What Does a Stock Split Mean?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.